Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Peritoneal Neoplasms 1 Nasopharyngeal Carcinoma 1 Colorectal Neoplasms 1 Colorectal Cancer Metastatic 1 Carcinosarcoma 1 Breast Neoplasms 1

Interventions

Bevacizumab 17 Capecitabine 13 Cetuximab 10 Oxaliplatin 8 Irinotecan 8 Fluorouracil 7 Panitumumab 5 Leucovorin 4 trifluridine tipiracil drug combination 3 sintilimab 3 regorafenib 3 Nivolumab 3 Ipilimumab 3 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Folfox protocol 2 Drug Therapy 2 spartalizumab 1 pembrolizumab 1 irinotecan sucrosofate 1 glucopyranosyl lipid-A 1 folfirinox 1 camrelizumab 1 balstilimab 1 anisodamine 1 aflibercept 1 XELOX 1 Vemurafenib 1 Tyrosine Kinase Inhibitors 1 Transurethral Resection of Prostate 1 Tomography, X-Ray Computed 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Colorectal Cancer Metastatic × LY-2157299 × Clear all

NCT03470350 2019-07-24

EORTC1615

The Netherlands Cancer Institute

Phase 1/2 Withdrawn

Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡